Latest Healthcare Research Reports

Tag: vaccine contract manufacturing market outlook

  • Vaccine Contract Manufacturing Market Size Projected To Increase From $4.27 Billion To $6.46 Billion During The Forecast Period

    Vaccine Contract Manufacturing Market Size Projected To Increase From $4.27 Billion To $6.46 Billion During The Forecast Period

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Vaccine Contract Manufacturing Market Expected To Reach $6.46 Billion By 2030 At 10.9% CAGR

    The market for vaccine contract manufacturing experienced robust expansion recently. Projections indicate a rise from $3.88 billion in 2025 to $4.27 billion in 2026, reflecting a compound annual growth rate of 10.0%. This upward trajectory during the past period is largely due to the broader scope of worldwide vaccination initiatives, the escalating intricacy involved in manufacturing vaccines, the increasing dependence on expert contract manufacturing firms, the proliferation of collaborative efforts between public and private sectors for vaccine development, and the establishment of significant vaccine production infrastructure.

    Regarding the vaccine contract manufacturing sector, a significant increase in its market value is anticipated over the upcoming years, projected to reach $6.46 billion by the year 2030, demonstrating a compound annual growth rate of 10.9%. This upward trajectory during the projected timeframe is fueled by several key factors, including the escalating need for swift vaccine production scaling, augmented investment flowing into mRNA and innovative vaccine technologies, the broadening of commercial-scale manufacturing operations, a heightened emphasis on nations achieving their own vaccine production independence, and the integration of sophisticated bioprocessing techniques. Furthermore, prominent developments expected within this period encompass a greater tendency for vaccine production to be contracted out, a surge in the requirement for adaptable manufacturing capacities, extensions in the services offered for filling and finishing vaccines, a stronger concentration on manufacturing processes that adhere to regulatory standards, and a more widespread adoption of disposable bioprocessing equipment.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Vaccine Contract Manufacturing Market Industry Drivers: What Is Driving Revenue Growth?

    The increasing prevalence of infectious diseases globally is anticipated to fuel the expansion of the vaccine contract manufacturing sector. Infectious diseases are conditions caused by disease-causing organisms including bacteria, viruses, fungi, or parasites, and their outbreaks, such as those involving influenza, measles, or novel viruses, necessitate a rapid increase in vaccine production to curb further transmission. Contract manufacturers possess the capability to swiftly enhance their output in reaction to these public health emergencies. Illustratively, data from the World Health Organization, a global health agency headquartered in Switzerland, indicated that in October 2024, roughly 8.2 million individuals received new tuberculosis diagnoses in 2023, an increase from approximately 7.5 million in 2022, positioning tuberculosis as the foremost fatal infectious disease, underscoring how the escalating global incidence of infectious diseases is a primary driver for the vaccine contract manufacturing market’s growth.

    Vaccine Contract Manufacturing Market Segment Landscape And Growth Potential

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    #Vaccine Contract Manufacturing Market Growth Trends: What Is Influencing The Future Outlook?

    Leading entities within the vaccine contract manufacturing sector are prioritizing the inauguration of new production facilities to solidify their market standing. The establishment of these vaccine contract manufacturing sites signifies the creation of dedicated operational bases for producing vaccines under contract. As an illustration, WuXi Vaccines, a Chinese contract development and manufacturing organization renowned for its vaccine expertise, inaugurated its inaugural independent vaccine CDMO facility in Suzhou, China, in September 2023. This strategic expansion significantly boosts the company’s capacity for both the manufacturing of the core vaccine components and the final drug product. Consequently, WuXi Vaccines now provides an all-encompassing suite of services that span various vaccine types, encompassing process refinement, drug product formulation, and the manufacturing of clinical-stage drug substances alongside sterile drug products in small to medium volumes. This newly commissioned independent facility amplifies WuXi Vaccines’ potential to participate in vaccine creation and production, thereby assuming a crucial role in propelling global health advancements.

    Vaccine Contract Manufacturing Market Competitive Landscape: Who Are The Leading Companies?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Access The Complete Vaccine Contract Manufacturing Market Report:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Vaccine Contract Manufacturing Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market Influenced by Strategic Expansion of Standalone Manufacturing Facilities

    Vaccine Contract Manufacturing Market Influenced by Strategic Expansion of Standalone Manufacturing Facilities

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Is The Market Size Of The Vaccine Contract Manufacturing Market Expected To Scale Between 2026 And 2030?

    The vaccine contract manufacturing market has demonstrated strong expansion in recent years. This market is projected to increase from $3.88 billion in 2025 to $4.27 billion in 2026, at a compound annual growth rate (CAGR) of 10.0%. The growth observed in the historic period can be attributed to the broadening of global immunization programs, the escalating complexity of vaccine production processes, an increased reliance on specialized contract manufacturers, the rise of public-private vaccine partnerships, and the establishment of substantial vaccine manufacturing facilities.

    The vaccine contract manufacturing market is projected for substantial expansion in the coming years, reaching a valuation of $6.46 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.9%. This anticipated growth during the forecast period stems from factors such as an escalating need for swift vaccine production scaling, heightened capital allocation towards mRNA and innovative vaccine types, the broadening of commercial manufacturing operations, an increasing emphasis on achieving regional vaccine independence, and the integration of cutting-edge bioprocess technologies. Key trends anticipated within the same forecast timeframe encompass a growing reliance on external providers for vaccine manufacturing, a heightened requirement for adaptable production capacities, the broadening of fill-finish service offerings, an intensifying focus on production adhering to regulatory standards, and a wider embrace of single-use bioprocessing solutions.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Which Drivers Are Supporting The Vaccine Contract Manufacturing Market Growth?

    The global increase in infectious diseases is anticipated to accelerate the expansion of the vaccine contract manufacturing market. These disorders originate from pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. When outbreaks occur, involving conditions like influenza, measles, or new viruses, an urgent requirement for vaccines emerges to prevent wider dissemination. Contract manufacturers are well-positioned to swiftly escalate production in response to these situations. For instance, in October 2024, the World Health Organization, an international public health organization based in Switzerland, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023. This marked an increase from about 7.5 million in 2022, establishing tuberculosis as the leading infectious disease killer. Hence, the growing prevalence of infectious diseases worldwide is a key factor driving the growth of the vaccine contract manufacturing market.

    How Is The Vaccine Contract Manufacturing Market Broken Down By Segment Categories?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    Which Trends Are Expected To Impact The Vaccine Contract Manufacturing Market?

    Key companies in the vaccine contract manufacturing market are strategically focusing on establishing new production sites to secure their market presence. The opening of a production site for vaccine contract manufacturing involves setting up a facility specifically designed for the contractual manufacturing and production of vaccines. For example, in September 2023, WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) specializing in vaccine discovery and production, opened its first dedicated vaccine CDMO facility in Suzhou, China. This expansion signifies a major achievement for the company, bringing about increased capabilities for both drug substance and drug product manufacturing. WuXi Vaccines now delivers an extensive array of services for various vaccines, including process development, drug product development, and the production of clinical-scale drug substances (DS) and small-to-medium sterile drug products (DP). The new standalone site strengthens WuXi Vaccines’ ability to contribute to vaccine development and manufacturing, playing a key role in advancing global healthcare solutions.

    Which Players Are Present In The Vaccine Contract Manufacturing Market Space?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Get The Full Vaccine Contract Manufacturing Market Report:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Which Geographic Region Dominates The Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Vaccine Contract Manufacturing Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2026, By The Business Research Company

    Antibody Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

    Biopharmaceuticals Contract Manufacturing Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Vaccines Market Report

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market Developments and Growth Opportunities Across 2026–2030

    Vaccine Contract Manufacturing Market Developments and Growth Opportunities Across 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Large Is The Vaccine Contract Manufacturing Market Projected To Become By 2030 Based On Its 2026 Valuation?

    The vaccine contract manufacturing market has experienced robust expansion in recent years. It is forecast to rise from $3.88 billion in 2025 to $4.27 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.0%. The past growth can be attributed to the broadening of global immunization initiatives, the escalating intricacy of vaccine production methods, a greater dependence on specialized contract manufacturers, the proliferation of public-private vaccine partnerships, and the establishment of extensive vaccine production facilities.

    The vaccine contract manufacturing market size is projected to experience substantial expansion over the upcoming years. By 2030, it is anticipated to reach $6.46 billion, exhibiting a compound annual growth rate (CAGR) of 10.9%. This anticipated expansion throughout the projected timeframe stems from factors such as heightened demand for swift vaccine scale-up, increased capital allocation towards mRNA and innovative next-generation vaccines, the broadening of commercial production facilities, a stronger emphasis on achieving regional vaccine autonomy, and the integration of cutting-edge bioprocess technologies. Key developments expected during this period involve a surge in the outsourcing of vaccine manufacturing, an escalating need for adaptable production capabilities, the enhancement of fill-finish service offerings, a sharpened focus on manufacturing processes that comply with regulations, and a greater embrace of single-use bioprocessing systems.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Which Market Drivers Are Supporting The Expansion Of The Vaccine Contract Manufacturing Market?

    The global increase in infectious diseases is projected to stimulate the expansion of the vaccine contract manufacturing market. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. During outbreaks of these diseases, including influenza, measles, or emerging viruses, there is a pressing requirement for vaccines to prevent further transmission, a need that contract manufacturers can address by quickly scaling up production. For instance, in October 2024, data from the World Health Organization, an international public health organization located in Switzerland, indicated that around 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from approximately 7.5 million in 2022, establishing tuberculosis as the leading infectious disease fatality. Therefore, the escalating prevalence of infectious diseases worldwide is a key driver for the growth of the vaccine contract manufacturing market.

    What Segment Groups Are Identified Within The Vaccine Contract Manufacturing Market?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    What Trends Are Affecting The Expansion Of The Vaccine Contract Manufacturing Market?

    Leading firms within the vaccine contract manufacturing market are prioritizing the establishment of new production sites for vaccine contract manufacturing as a strategy to maintain their competitive standing. A production site opening in vaccine contract manufacturing signifies the creation of a specialized facility dedicated to the contractual manufacturing and production of vaccines. An illustrative example occurred in September 2023 when WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) specializing in vaccine discovery and production, inaugurated its initial dedicated vaccine CDMO site in Suzhou, China. This expansion represents a significant achievement for the company, enhancing its capacities for both drug substance and drug product manufacturing. WuXi Vaccines now provides a full spectrum of services for various vaccines, encompassing process development, drug product development, and the manufacturing of clinical-scale drug substances (DS) along with small-to-medium sterile drug products (DP). The newly independent site boosts WuXi Vaccines’ ability to contribute to vaccine development and manufacturing, thereby playing a crucial part in advancing worldwide healthcare solutions.

    Which Companies Hold Significant Positions In The Vaccine Contract Manufacturing Market?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Read the full vaccine contract manufacturing market report here:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    How Is The Vaccine Contract Manufacturing Market Distributed Across Key Geographic Regions?

    North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Vaccine Contract Manufacturing Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2026, By The Business Research Company

    Antibody Contract Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

    Biopharmaceuticals Contract Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Vaccines Global Market Report

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market Future Outlook 2026: Key Drivers and Growth Potential

    Vaccine Contract Manufacturing Market Future Outlook 2026: Key Drivers and Growth Potential

    Uncover key drivers, emerging technologies, and competitive movements shaping the vaccine contract manufacturing market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Vaccine Contract Manufacturing Market in 2030?

    The vaccine contract manufacturing market size has experienced significant expansion in recent years. This market is projected to expand from $3.88 billion in 2025 to $4.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.0%. Historically, this growth was driven by factors such as the broadening of global immunization initiatives, the escalating intricacy of vaccine production methods, a greater dependence on specialized contract manufacturers, the rise of public-private collaborations in vaccines, and the development of extensive vaccine production facilities.

    The vaccine contract manufacturing market is projected to experience substantial expansion in the coming years. This market is set to reach $6.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This anticipated growth over the forecast period stems from factors such as an escalating need for swift vaccine scale-up, augmented investments in mRNA and advanced vaccine types, the broadening of commercial-scale production, an intensifying emphasis on achieving regional vaccine autonomy, and the integration of cutting-edge bioprocess technologies. Key trends during this period are expected to encompass a surge in the outsourcing of vaccine manufacturing, an elevated requirement for adaptable production capacities, the broadening of fill-finish service offerings, a heightened commitment to manufacturing compliant with regulations, and a greater uptake of single-use bioprocessing systems.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    What Drivers Are Influencing Production Trends In The Vaccine Contract Manufacturing Market?

    The global rise in infectious diseases is anticipated to stimulate the expansion of the vaccine contract manufacturing market. Infectious diseases are defined as conditions caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. When outbreaks of infectious diseases occur, like influenza, measles, or emerging viruses, there is an immediate requirement for vaccines to prevent wider dissemination. Contract manufacturers are capable of rapidly scaling up production to address these outbreaks. For instance, in October 2024, the World Health Organization, an international public health organization based in Switzerland, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from about 7.5 million in 2022, solidifying tuberculosis’s position as the leading infectious disease killer. Therefore, the growing prevalence of infectious diseases worldwide is fueling the growth of the vaccine contract manufacturing market.

    Which Segments Are Gaining Traction In The Vaccine Contract Manufacturing Market?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    Which Trends Are Shaping Activity Within The Vaccine Contract Manufacturing Market?

    Major companies engaged in the vaccine contract manufacturing market are prioritizing the establishment of new production sites to sustain their competitive edge. The opening of such facilities pertains to setting up dedicated sites for the contractual manufacturing and production of vaccines. For example, in September 2023, WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) focused on vaccine discovery and production, launched its first independent vaccine CDMO site in Suzhou, China. This expansion signifies a major milestone for the company, introducing enhanced capabilities for both drug substance and drug product manufacturing. WuXi Vaccines now provides a full spectrum of services, including process development, drug product development, and the production of clinical-scale drug substances (DS) and small-to-medium sterile drug products (DP). The new standalone facility significantly increases WuXi Vaccines’ capacity to contribute to vaccine development and manufacturing, thereby playing a vital role in advancing global healthcare solutions.

    Who Are The Major Companies Operating In The Vaccine Contract Manufacturing Market?

    Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Which Global Regions Are Shaping The Competitive Landscape Of The Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Vaccine Contract Manufacturing Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2026, By The Business Research Company

    Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Antibody Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

    Biopharmaceuticals Contract Manufacturing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

    Vaccine Contract Manufacturing Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Is The Vaccine Contract Manufacturing Market Expected To Grow In Terms Of Size?

    The market size of vaccine contract manufacturing has seen robust growth in the past few years. It is projected to expand from $3.58 billion in 2024 to $3.88 billion in 2025, witnessing a compound annual growth rate (CAGR) of 8.4%. The impressive growth in the historical phase can be linked to factors such as limitations in conventional vaccine manufacturing, the rise in global disease outbreaks, which has increased the demand for vaccines, regulatory backing for contract manufacturing, heightened complexity in vaccine production processes and a boom in vaccine research and development.

    In the coming years, a rapid expansion is anticipated in the vaccine contract manufacturing market, with its size swelling to $5.78 billion in 2029 at a compound annual growth rate of 10.4%. The projected growth in this period can be linked to an increasing focus on readiness for pandemics, a rise in pharmaceutical manufacturing outsourcing, spread of biopharmaceutical companies, shortened vaccine development schedules, and worldwide initiatives promoting access to vaccines. Key trends expected during this forecast period comprise the incorporation of single-use technologies in manufacturing, a surge in bespoke approaches to vaccine creation, progress in mRNA and viral vector vaccines, adoption of uninterrupted manufacturing procedures, and extension of fill-finish services.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    What Are The Primary Factors Supporting The Vaccine Contract Manufacturing Market Expansion?

    The projected growth of the vaccine contract manufacturing market is attributed to escalating initiatives promoting vaccinations. Vaccination, an effective, safe, and simple method to prevent infectious diseases, strengthens the immune system and augments the body’s resistance to infections. An upsurge in such supportive programs is forecasted to enhance various vaccine manufacturing procedures, facilitating vaccine contract manufacturing. The U.S. Department of Health and Human Services, a cabinet-level executive branch in the US federal government, announced in November 2022 a fresh initiative – generously funded with $350 million – for HRSA-supported health facilities to increase the distribution of COVID-19 vaccines among their communities, primarily focusing on marginalized populations. Consequently, the growing focus on measures promoting vaccination is fueling the expansion of the vaccine contract manufacturing market.

    Which Segmentation Categories Are Highlighted In The Vaccine Contract Manufacturing Market Analysis?

    The vaccine contract manufacturingmarket covered in this report is segmented –

    1) By Service Type: Fill-Finish; Bulk Product

    2) By Vaccine Type: Inactivated Vaccines; Live-Attenuated Vaccines; RNA (Ribonucleic Acid) Vaccines; Subunit Vaccines; Toxoid-Based Vaccines

    3) By Process: Downstream; Upstream

    4) By Scale Of Operation: Preclinical; Clinical; Commercial

    5) By End-Use: Human Use; Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish; Lyophilization; Vial Filling; Syringe Filling

    2) By Bulk Product: Cell Culture; Microbial Fermentation; Antigen Production; Buffer Preparation

    Which Notable Trends Are Transforming The Vaccine Contract Manufacturing Market Outlook?

    The notable uptick in strategic collaborations is a predominant trend to watch in the vaccine contract manufacturing sector. Leading corporations are joining forces with operating companies in this industry to uphold their market standing. For example, in January 2023, Vaxxas, a biotechnology company from Australia that specializes in innovative needle-free vaccination technology, entered a collaboration with the Coalition for Epidemic Preparedness Innovations – a foundation based in Norway. This partnership is intended to support and streamline the creation of new vaccines, focusing on promoting Vaxxas’ needle-free vaccine patch delivery technology – a revolutionary solution that might negate the need for frozen mRNA vaccine storage. Moreover, in October 2024, LenioBio, a biotech firm based in Germany, aligned with ReciBioPharm, an American Contract Development and Manufacturing Organization (CDMO) to bolster its protein production capacity and expedite vaccine manufacturing. This strategic alliance chimes with LenioBio’s plan to broaden its CEPI-funded project and demonstrate the promptness and efficacy of its unique ALiCE protein expression technology in the production of vaccine-associated proteins for clinical trials application.

    Which Organizations Are At The Forefront Of The Vaccine Contract Manufacturing Market?

    Major companies operating in the vaccine contract manufacturing market include Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Fujifilm Holdings Corporation, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Icon plc, Lonza Group AG, Cytiva, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Albany Molecular Research Inc., Soligenix Inc., Bio Farma, Curia Global Inc., Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Which Geographic Regions Are Creating Strong Demand In The Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2025, By The Business Research Company

    Orphan Drug Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/orphan-drug-global-market-report

    Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Autoimmune Disease Diagnosis Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market to Grow at a CAGR of 10.4% from 2025 to 2029

    Vaccine Contract Manufacturing Market to Grow at a CAGR of 10.4% from 2025 to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Are The Growth Projections For The Vaccine Contract Manufacturing Market Size During 2025–2029?

    The vaccine contract manufacturing market size has seen substantial growth over recent years. Its valuation is projected to expand from $3.58 billion in 2024 to $3.88 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 8.4%. The factors contributing to this market’s expansion in past periods include restrictions in traditional vaccine manufacturing, global disease outbreaks stimulating the need for vaccines, governmental support for contract manufacturing, the rising complexity involved in vaccine creation, and a surge in the fields of vaccine research and development.

    The vaccine contract manufacturing market is projected to experience substantial growth in the coming years. It is set to expand to $5.78 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period is attributable to an increasing emphasis on pandemic preparedness, a rise in outsourcing within pharmaceutical manufacturing, the growth of biopharmaceutical companies, accelerated vaccine development timelines, and global initiatives promoting vaccine accessibility. Prominent trends for this period include the integration of single-use technologies in manufacturing, an increase in personalized medicine approaches to vaccine development, the advancement of mRNA and viral vector vaccines, the adoption of continuous manufacturing processes, and the broadening of fill-finish services.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Which Drivers Are Shaping The Vaccine Contract Manufacturing Industry’s Market Share?

    Future expansion of the vaccine contract manufacturing market is anticipated due to a rise in pro-vaccination endeavors. Vaccination constitutes a straightforward, secure, and effective means of preventing infectious diseases. It strengthens the immune system, enhancing the body’s resistance to infections. A greater number of initiatives supporting vaccinations would facilitate the progression and refinement of diverse vaccine manufacturing processes, thereby supporting vaccine contract manufacturing. As an illustration, in November 2022, the U.S. Department of Health and Human Services, a cabinet-level executive branch department of the US federal government, unveiled a new $350 million program targeting HRSA (Health Resources and Services Administration)-supported health centers to elevate COVID-19 vaccine uptake in their localities, particularly focusing on underserved populations. Consequently, the uptick in initiatives promoting vaccinations is fueling the expansion of the vaccine contract manufacturing market.

    What Are The Segment Types Shaping The Vaccine Contract Manufacturing Market?

    The vaccine contract manufacturingmarket covered in this report is segmented –

    1) By Service Type: Fill-Finish; Bulk Product

    2) By Vaccine Type: Inactivated Vaccines; Live-Attenuated Vaccines; RNA (Ribonucleic Acid) Vaccines; Subunit Vaccines; Toxoid-Based Vaccines

    3) By Process: Downstream; Upstream

    4) By Scale Of Operation: Preclinical; Clinical; Commercial

    5) By End-Use: Human Use; Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish; Lyophilization; Vial Filling; Syringe Filling

    2) By Bulk Product: Cell Culture; Microbial Fermentation; Antigen Production; Buffer Preparation

    What Are The Latest Industry Trends Transforming The Vaccine Contract Manufacturing Market?

    Strategic alliances represent a significant evolving trend within the vaccine contract manufacturing industry. Leading companies are forming collaborations with businesses active in the vaccine contract manufacturing domain to maintain their standing in the market. As an illustration, in January 2023, Vaxxas, an Australian biotechnology company focused on developing innovative needle-free vaccination technology, collaborated with the Coalition for Epidemic Preparedness Innovations (CEPI), a foundation based in Norway. This partnership’s objective is to finance and coordinate the creation of new vaccines and foster the advancement of Vaxxas’ needle-free vaccine patch delivery technology in a venture that may remove the need for frozen storage of mRNA vaccines. Additionally, in October 2024, LenioBio, a German Biotech firm, teamed up with ReciBioPharm, a US-based contract development and manufacturing organization (CDMO), to expand its protein manufacturing capabilities and quicken vaccine production. This collaboration is consistent with LenioBio’s plan to extend the scope of its CEPI-supported project, which aims to demonstrate the swiftness and efficiency of its unique ALiCE protein expression technology in producing proteins related to vaccines for use in clinical trials.

    Who Are The Top Performing Companies In The Vaccine Contract Manufacturing Market In Recent Years?

    Major companies operating in the vaccine contract manufacturing market include Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Fujifilm Holdings Corporation, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Icon plc, Lonza Group AG, Cytiva, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Albany Molecular Research Inc., Soligenix Inc., Bio Farma, Curia Global Inc., Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Which Region Currently Holds The Largest Share Of The Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Vaccine Contract Manufacturing Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    Browse Through More Reports Similar to the Global Vaccine Contract Manufacturing Market 2025, By The Business Research Company

    Orphan Drug Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/orphan-drug-global-market-report

    Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Autoimmune Disease Diagnosis Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Jynneos Market Outlook 2025 – Insights for Executive and Strategic Planning

    Jynneos Market Outlook 2025 – Insights for Executive and Strategic Planning

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Fast Is The Jynneos Market Expected to Grow Between 2025 And 2029?

    Recently, the jynneos market has observed a XX (HCAGR). It is projected to expand from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. The historic growth can be credited to factors such as the escalating threat of emergent infectious diseases, an increase in governmental vaccine funding, a surge in global travel, increased public health initiatives, and enhancements in the vaccine supply chain.

    What Growth Rate Is Anticipated for the Jynneos Market in the Coming Years?

    In the coming years, the market size of Jynneos is predicted to witness a compound annual growth rate (CAGR) of XX%, escalating to a value of $XX million by the year 2029. The significant growth during this forecast period could be contributed to several factors. These include the rising trend in infection prevention, the growth of personalized medicine, escalated focus on preparedness of the health system against infectious diseases, increased investment in creating and delivering vaccine infrastructure, and a surge in people with weakened immune systems. The key trends expected to shape this period will be improvements in treatment procedures, the introduction of mRNA vaccine technology, the use of Artificial Intelligence (AI) in vaccine development, progress in adjuvant systems, and the emergence of novel formulations.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    Who Are the Leading Companies in the Jynneos Market?

    Major companies operating in the jynneos market include Bavarian Nordic A/S

    What Are the Key Drivers of the Jynneos Market?

    The surge in monkeypox cases is projected to propel the growth of the Jynneos market. Monkeypox is an infectious disease propagated by the monkeypox virus, a member of the orthopoxvirus family. The increasing incidences of monkeypox are attributed to escalated global travel and heightened interaction between wildlife and humans, which allows for quick transmission of infectious agents, turning isolated outbreaks. Jynneos provides effective defense against the virus in susceptible individuals and presents less risk for those with weak immune systems compared to conventional smallpox vaccines. For example, a report from the European Centre for Disease Prevention and Control, a European government institution, in September 2024 stated that from January 2022 to July 2024, over 100,000 confirmed cases of pox owing to monkeypox virus (MPXV) clade I and clade II, along with over 200 fatalities, were reported across 120+ countries worldwide. Also, the European Centre for Disease Prevention and Control (ECDC), a governmental organization based in Sweden, reported in May 2022 that from January to April 2022, there were 1,152 suspected monkeypox cases, leading to 55 fatalities and a case-fatality rate of 4.8%, spread across 54 health zones in 14 provinces. Hence, the rising incidences of monkeypox are fueling the expansion of the Jynneos market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=20118&type=smp

    What Are the Key Market Segments in the Jynneos Industry?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    What Are the Key Regional Markets in the Jynneos Industry?

    North America was the largest region in the jynneos market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20118

    This Report Delivers Insight On:

    1. How big is the jynneos market, and how is it changing globally?

    2. Who are the major companies in the jynneos market, and how are they performing?

    3. What are the key opportunities and risks in the jynneos market right now?

    4. Which products or customer segments are growing the most in the jynneos market?

    5. What factors are helping or slowing down the growth of the jynneos market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Vaccine Contract Manufacturing Market to Reach $5.93 Billion by 2029 | Key Drivers and Future Outlook

    Vaccine Contract Manufacturing Market to Reach $5.93 Billion by 2029 | Key Drivers and Future Outlook

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Vaccine Contract Manufacturing Market?

    The market size for vaccine contract manufacturing has seen a significant surge recently. It is projected to swell from $3.58 billion in 2024 to $3.93 billion in 2025, marking a compound annual growth rate (CAGR) of 9.7%. This increase in the past years can be traced back to traditional limitations in vaccine manufacturing, heightened demand for vaccines due to global disease spreads, regulatory approval supporting contract manufacturing, the escalating intricacy in the production of vaccines, as well as a dramatic increase in vaccine research and development.

    What Growth Rate Is Forecasted for the Vaccine Contract Manufacturing Market by 2029?

    The market size for vaccine contract manufacturing is set to experience accelerated expansion in the upcoming years, with predictions pointing to a growth to $5.93 billion by the year 2029, marking a compound annual growth rate (CAGR) of 10.8%. The principal reasons stimulating growth throughout the forecast period include an intensifying focus on being prepared for pandemics, a surge in outsourcing within the pharmaceutical manufacturing sector, the growth of biopharmaceutical establishments, fast-tracked vaccine production timelines, and worldwide efforts to ensure vaccine availability. Key trends projected for the forecast interval incorporate the assimilation of single-use technologies in the manufacturing process, the emergence of personalized medicine for vaccine development, the growth of mRNA and viral vector vaccines, the adoption of continuous manufacturing procedures, and the broadening of fill-finish services.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    Which Key Companies Are Shaping the Future of the Vaccine Contract Manufacturing Market?

    Major companies operating in the vaccine contract manufacturing market include Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Fujifilm Holdings Corporation, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Icon plc, Lonza Group AG, Cytiva, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Albany Molecular Research Inc., Soligenix Inc., Bio Farma, Curia Global Inc., Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

    Which Factors Are Driving Demand in the Vaccine Contract Manufacturing Industry?

    The expansion of the vaccine contract manufacturing market is anticipated to be fueled by rising initiatives promoting vaccinations. These vaccinations are a simple, effective, and safe mechanism to prevent infectious diseases from spreading, strengthening the immune system and increasing resilience against infections. The augmentation of these initiatives can stimulate enhancement and progression in various vaccine manufacturing procedures, thereby supporting vaccine contract manufacturing. As an illustration, in November 2022, the U.S. Department of Health and Human Services, a US government organ at the cabinet level, divulged a new initiative of $350 million for HRSA-supported health establishments to amplify the volume of COVID-19 vaccines in their respective communities, focusing particularly on underserved individuals. Consequently, the surge in initiatives promoting vaccinations is propelling the expansion of the vaccine contract manufacturing market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    How Is the Vaccine Contract Manufacturing Market Segmented by Several Divisions?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    What are the Emerging Market Trends Driving the Growth of the Vaccine Contract Manufacturing Industry?

    Collaborative efforts are becoming an increasingly popular trend within the vaccine contract manufacturing sector. To maintain their standing in the market, major players are forming alliances with other companies within the same industry. For example, in January 2023, Vaxxas, an Australian biotech firm specializing in innovative needle-free vaccination methods, teamed up with the Norway-based Coalition for Epidemic Preparedness Innovations. This partnership was arranged to fund and supervise the creation of new vaccines and help advance Vaxxas’ needle-free vaccine patch delivery technology which could potentially eliminate the need for frozen storage of mRNA vaccines. Additionally, in October 2024, LenioBio, a German biotech company, joined forces with ReciBioPharm, a US-based contract development and manufacturing company, in order to boost their protein production capabilities and hasten the process of producing vaccines. This partnership is in line with LenioBio’s strategy to broaden the reach of its CEPI-financed project aimed at demonstrating the effectiveness and efficiency of its proprietary ALiCE protein expression technology for the generation of vaccine-related proteins suitable for clinical trials.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    Which Regions Are Driving Growth in the Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12216

    This Report Delivers Insight On:

    1. How big is the vaccine contract manufacturing market, and how is it changing globally?

    2. Who are the major companies in the vaccine contract manufacturing market, and how are they performing?

    3. What are the key opportunities and risks in the vaccine contract manufacturing market right now?

    4. Which products or customer segments are growing the most in the vaccine contract manufacturing market?

    5. What factors are helping or slowing down the growth of the vaccine contract manufacturing market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • $5.93 Billion Forecast for Vaccine Contract Manufacturing Market by 2029, Backed by Demand and Innovation

    $5.93 Billion Forecast for Vaccine Contract Manufacturing Market by 2029, Backed by Demand and Innovation

    Discover trends, market shifts, and competitive outlooks for the vaccine contract manufacturing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    How Has the Vaccine Contract Manufacturing Market Growth Performance Trended Historically, And What Lies Ahead?

    The market size for vaccine contract manufacturing has seen a significant surge recently. It is projected to swell from $3.58 billion in 2024 to $3.93 billion in 2025, marking a compound annual growth rate (CAGR) of 9.7%. This increase in the past years can be traced back to traditional limitations in vaccine manufacturing, heightened demand for vaccines due to global disease spreads, regulatory approval supporting contract manufacturing, the escalating intricacy in the production of vaccines, as well as a dramatic increase in vaccine research and development.

    The market size for vaccine contract manufacturing is set to experience accelerated expansion in the upcoming years, with predictions pointing to a growth to $5.93 billion by the year 2029, marking a compound annual growth rate (CAGR) of 10.8%. The principal reasons stimulating growth throughout the forecast period include an intensifying focus on being prepared for pandemics, a surge in outsourcing within the pharmaceutical manufacturing sector, the growth of biopharmaceutical establishments, fast-tracked vaccine production timelines, and worldwide efforts to ensure vaccine availability. Key trends projected for the forecast interval incorporate the assimilation of single-use technologies in the manufacturing process, the emergence of personalized medicine for vaccine development, the growth of mRNA and viral vector vaccines, the adoption of continuous manufacturing procedures, and the broadening of fill-finish services.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12216&type=smp

    What Are the Core Growth Drivers Propelling the Vaccine Contract Manufacturing Market Forward?

    The expansion of the vaccine contract manufacturing market is anticipated to be fueled by rising initiatives promoting vaccinations. These vaccinations are a simple, effective, and safe mechanism to prevent infectious diseases from spreading, strengthening the immune system and increasing resilience against infections. The augmentation of these initiatives can stimulate enhancement and progression in various vaccine manufacturing procedures, thereby supporting vaccine contract manufacturing. As an illustration, in November 2022, the U.S. Department of Health and Human Services, a US government organ at the cabinet level, divulged a new initiative of $350 million for HRSA-supported health establishments to amplify the volume of COVID-19 vaccines in their respective communities, focusing particularly on underserved individuals. Consequently, the surge in initiatives promoting vaccinations is propelling the expansion of the vaccine contract manufacturing market.

    What Segment Types Define the Vaccine Contract Manufacturing Market Structure?

    The vaccine contract manufacturing market covered in this report is segmented –

    1) By Service Type: Fill-Finish, Bulk Product

    2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines

    3) By Process: Downstream, Upstream

    4) By Scale Of Operation: Preclinical, Clinical, Commercial

    5) By End-Use: Human Use, Veterinary

    Subsegments:

    1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling

    2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=12216&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Vaccine Contract Manufacturing Market?

    North America was the largest region in the vaccine contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Emerging Trends that Are Influencing theVaccine Contract Manufacturing Industry Evolution?

    Collaborative efforts are becoming an increasingly popular trend within the vaccine contract manufacturing sector. To maintain their standing in the market, major players are forming alliances with other companies within the same industry. For example, in January 2023, Vaxxas, an Australian biotech firm specializing in innovative needle-free vaccination methods, teamed up with the Norway-based Coalition for Epidemic Preparedness Innovations. This partnership was arranged to fund and supervise the creation of new vaccines and help advance Vaxxas’ needle-free vaccine patch delivery technology which could potentially eliminate the need for frozen storage of mRNA vaccines. Additionally, in October 2024, LenioBio, a German biotech company, joined forces with ReciBioPharm, a US-based contract development and manufacturing company, in order to boost their protein production capabilities and hasten the process of producing vaccines. This partnership is in line with LenioBio’s strategy to broaden the reach of its CEPI-financed project aimed at demonstrating the effectiveness and efficiency of its proprietary ALiCE protein expression technology for the generation of vaccine-related proteins suitable for clinical trials.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

    What Is the Definition of the Vaccine Contract Manufacturing Market?

    Vaccine contract manufacturing refers to an arrangement for creating vaccines with outside producers, who oversee producing, packing, and labeling vaccines according to the specifications and demands of the contracting business or organization. The primary benefit of vaccine contract manufacturing is that it simplifies production, resulting in cost savings and fewer difficulties.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12216

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Jynneos Market Forecast and Insights: Exploring Growth Trends, Market Size, and Emerging Opportunities

    Jynneos Market Forecast and Insights: Exploring Growth Trends, Market Size, and Emerging Opportunities

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    How Are Key Drivers Contributing to the Growth and Expansion of the Jynneos Market?

    The growth of the jynneos market is driven by the rising prevalence of monkeypox cases. Monkeypox is a viral disease that spreads through global travel and human-wildlife interaction. Jynneos effectively prevents the virus in at-risk individuals and is safer for those with weakened immune systems compared to traditional smallpox vaccines. According to the European Centre for Disease Prevention and Control, over 100,000 monkeypox cases were reported globally from January 2022 to July 2024. The increasing number of monkeypox cases is propelling the growth of the jynneos market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20118&type=smp

    #How Will the CAGR of the Jynneos Market Influence Its Overall Growth by 2034?

    The jynneos market size has XX (HCAGR) in recent years. It will expand from $XX million in 2024 to $XX million in 2025 at a CAGR of XX%. Growth is due to increasing infectious disease risks, vaccination funding, travel rise, health campaigns, and vaccine supply improvements.

    The jynneos market is projected to grow at XX (FCAGR) in the next few years. By 2029, it will reach $XX million at a CAGR of XX%. Growth is attributed to the shift toward infection prevention, personalized medicine, increased focus on health system preparedness, investments in vaccine infrastructure, and rising immunocompromised individuals. Key trends include advancements in treatments, mRNA vaccine technology, AI in vaccine development, advanced adjuvant systems, and innovative formulations.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20118

    Who Are the Leading Market Players Fueling Growth in the Jynneos Market Trend?

    Major companies operating in the jynneos market include Bavarian Nordic A/S

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/jynneos-global-market-report

    How is the Global Jynneos Market Segemented?

    The jynneos market covered in this report is segmented –

    1) By Indication: Prevention of Monkeypox, Prevention of Smallpox

    2) By Formulation: Injectable Formulation, Lyophilized Powder for Reconstitution

    3) By Patient Demographics: Adult Patients, Pediatric Patients, High-Risk Populations

    4) By Distribution channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

    5) By End User: Hospitals, Specialty Clinics, Public Health Organizations, Home Healthcare Providers

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=20118&type=smp

    Which Geographics are Influencing the Growth of the Jynneos Market?

    North America was the largest region in the jynneos market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the jynneos market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Browse Through More Reports Similar to the Global Jynneos Market 2025, By The Business Research Company:

    Chickenpox Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

    Monkey Pox Testing Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/monkey-pox-testing-global-market-report

    thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report

    https://www.thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: